Get startedLog in
    Picture of TAHO Pharmaceuticals logo

    6467 — TAHO Pharmaceuticals Income Statement

    0.000.00%
    tw flag iconLast trade - 00:00
    HealthcareHighly SpeculativeSmall CapMomentum Trap
    Balance sheetIncome statementCashflow
    Subscribe to view all data

    Annual income statement for TAHO Pharmaceuticals, fiscal year end - December 31st, TWD millions except per share, conversion factor applied.

    2021
    December 31st
    2022
    December 31st
    2023
    December 31st
    2024
    December 31st
    2025
    December 31st
    Period Length:12 M12 M12 M12 M12 M
    Source:PROSPECTUSPROSPECTUSPROSPECTUSAnnual Audited AccountsAnnual Audited Accounts
    Standards:
    IFRS
    IFRS
    IFRS
    IFRS
    IFRS
    Status:FinalFinalFinalFinalFinal
    Revenue
    Total Revenue6.896.361.0708.41
    Cost of Revenue
    Gross Profit5.675.06-0.07205.41
    Selling / General / Administrative Expenses
    Research And Development
    Total Operating Expenses81.373.1122170229
    Operating Profit-74.4-66.7-121-170-220
    Total Net Non Operating Interest Income / Expense
    Total Net Non Operating Interest Income / Expense
    Other Net Non Operating Costs
    Net Income Before Taxes-11.4-66.3-121-167-214
    Provision for Income Taxes
    Net Income After Taxes-11.4-66.3-121-167-214
    Net Income Before Extraordinary Items
    Net Income-11.4-66.3-121-167-214
    Income Available to Common Shareholders Excluding Extraordinary Items
    Income Available to Common Shareholders Including Extraordinary Items
    Diluted Net Income-11.4-66.3-121-167-214
    Diluted Weighted Average Shares
    Basic EPS Including Extraordinary Items
    Diluted EPS Including Extraordinary Items
    Diluted EPS Excluding Extraordinary Items
    Normalised Income Before Taxes
    Normalised Income After Taxes
    Normalised Income Available to Common Shareholders
    Diluted Normalised EPS-0.223-1.29-2.35-3.68-4.16
    Dividends per Share